540 related articles for article (PubMed ID: 33881501)
1. Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.
Greenberg HZE; Zhao G; Shah AM; Zhang M
Cardiovasc Res; 2022 May; 118(6):1433-1451. PubMed ID: 33881501
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Oxidative Stress (OS) in Calcific Aortic Valve Disease (CAVD): From Pathophysiology to Therapeutic Targets.
Tanase DM; Valasciuc E; Gosav EM; Floria M; Costea CF; Dima N; Tudorancea I; Maranduca MA; Serban IL
Cells; 2022 Aug; 11(17):. PubMed ID: 36078071
[TBL] [Abstract][Full Text] [Related]
3. COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification.
Vieceli Dalla Sega F; Fortini F; Cimaglia P; Marracino L; Tonet E; Antonucci A; Moscarelli M; Campo G; Rizzo P; Ferrari R
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255450
[TBL] [Abstract][Full Text] [Related]
4. The Role of Apoptosis and Oxidative Stress in a Cell Spheroid Model of Calcific Aortic Valve Disease.
Coutts CW; Baldwin AM; Jebeli M; Jolin GE; Mungai RW; Billiar KL
Cells; 2023 Dec; 13(1):. PubMed ID: 38201249
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-β1 promotes fibrosis but attenuates calcification of valvular tissue applied as a three-dimensional calcific aortic valve disease model.
Jenke A; Kistner J; Saradar S; Chekhoeva A; Yazdanyar M; Bergmann AK; Rötepohl MV; Lichtenberg A; Akhyari P
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1123-H1141. PubMed ID: 32986963
[TBL] [Abstract][Full Text] [Related]
6. Targeting vasoactive peptides for managing calcific aortic valve disease.
Peltonen T; Ohukainen P; Ruskoaho H; Rysä J
Ann Med; 2017 Feb; 49(1):63-74. PubMed ID: 27585243
[TBL] [Abstract][Full Text] [Related]
7. Deletion of calponin 2 attenuates the development of calcific aortic valve disease in ApoE
Plazyo O; Liu R; Moazzem Hossain M; Jin JP
J Mol Cell Cardiol; 2018 Aug; 121():233-241. PubMed ID: 30053524
[TBL] [Abstract][Full Text] [Related]
8. Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way.
En Q; Zeping H; Yuetang W; Xu W; Wei W
Mol Med; 2021 Dec; 27(1):156. PubMed ID: 34895136
[TBL] [Abstract][Full Text] [Related]
9. In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.
van der Ven CF; Wu PJ; Tibbitt MW; van Mil A; Sluijter JP; Langer R; Aikawa E
Clin Sci (Lond); 2017 Feb; 131(3):181-195. PubMed ID: 28057890
[TBL] [Abstract][Full Text] [Related]
10. Identification of hub genes in calcific aortic valve disease.
Lai QC; Zheng J; Mou J; Cui CY; Wu QC; M Musa Rizvi S; Zhang Y; Li TM; Ren YB; Liu Q; Li Q; Zhang C
Comput Biol Med; 2024 Apr; 172():108214. PubMed ID: 38508057
[TBL] [Abstract][Full Text] [Related]
11. Simulation of early calcific aortic valve disease in a 3D platform: A role for myofibroblast differentiation.
Hjortnaes J; Goettsch C; Hutcheson JD; Camci-Unal G; Lax L; Scherer K; Body S; Schoen FJ; Kluin J; Khademhosseini A; Aikawa E
J Mol Cell Cardiol; 2016 May; 94():13-20. PubMed ID: 26996755
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and valvular endothelial cells in aortic valve calcification.
Shu L; Yuan Z; Li F; Cai Z
Biomed Pharmacother; 2023 Jul; 163():114775. PubMed ID: 37116353
[TBL] [Abstract][Full Text] [Related]
13. Multiscale computational modeling of aortic valve calcification.
Azimi-Boulali J; Mahler GJ; Murray BT; Huang P
Biomech Model Mechanobiol; 2024 Apr; 23(2):581-599. PubMed ID: 38093148
[TBL] [Abstract][Full Text] [Related]
14. Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?
Broeders W; Bekkering S; El Messaoudi S; Joosten LAB; van Royen N; Riksen NP
Basic Res Cardiol; 2022 May; 117(1):28. PubMed ID: 35581364
[TBL] [Abstract][Full Text] [Related]
15. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops.
Li C; Xu S; Gotlieb AI
Cardiovasc Pathol; 2013; 22(1):1-8. PubMed ID: 22795219
[TBL] [Abstract][Full Text] [Related]
16. Sex-Specific Features of Calcific Aortic Valve Disease.
Summerhill VI; Moschetta D; Orekhov AN; Poggio P; Myasoedova VA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781508
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductase family 1 member B induces aortic valve calcification by activating hippo signaling in valvular interstitial cells.
Gao C; Hu W; Liu F; Zeng Z; Zhu Q; Fan J; Chen J; Cheng S; Yu K; Qian Y; Ren T; Zhao J; Liu X; Wang J
J Mol Cell Cardiol; 2021 Jan; 150():54-64. PubMed ID: 33045251
[TBL] [Abstract][Full Text] [Related]
18. ApoC-III is a novel inducer of calcification in human aortic valves.
Schlotter F; de Freitas RCC; Rogers MA; Blaser MC; Wu PJ; Higashi H; Halu A; Iqbal F; Andraski AB; Rodia CN; Kuraoka S; Wen JR; Creager M; Pham T; Hutcheson JD; Body SC; Kohan AB; Sacks FM; Aikawa M; Singh SA; Aikawa E
J Biol Chem; 2021; 296():100193. PubMed ID: 33334888
[TBL] [Abstract][Full Text] [Related]
19. Development of calcific aortic valve disease: Do we know enough for new clinical trials?
Kostyunin AE; Yuzhalin AE; Ovcharenko EA; Kutikhin AG
J Mol Cell Cardiol; 2019 Jul; 132():189-209. PubMed ID: 31136747
[TBL] [Abstract][Full Text] [Related]
20. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments.
Myasoedova VA; Ravani AL; Frigerio B; Valerio V; Moschetta D; Songia P; Poggio P
Pharmacol Res; 2018 Oct; 136():74-82. PubMed ID: 30149054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
